SAB Biotherapeutics, Inc. (SAB BIO)

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing multi-specific, high-potency human immunoglobulin G (hIgG) therapies to treat and prevent immune and autoimmune disorders. The company's mission is to redefine the treatment paradigm for Type 1 Diabetes (T1D) by developing disease-modifying medicines that address the underlying causes of the disease rather than just managing symptoms. Headquartered in Miami Beach, Florida, SAB Biotherapeutics was founded in 2014 and has been publicly traded on Nasdaq since 2021.

Utilizing advanced genetic engineering and antibody science, SAB Biotherapeutics employs its proprietary DiversitAb™ platform, which involves transchromosomic cattle (Tc-Bovine™), to produce fully human antibodies. This innovative approach eliminates the need for human donors or convalescent plasma. The company's lead product candidate, SAB-142, is a multi-specific, fully human anti-thymocyte globulin (hATG) specifically designed for autoimmune Type 1 Diabetes. SAB-142 aims to be a disease-modifying therapeutic that can delay the onset and potentially prevent the progression of Stage 3 T1D.

In recent developments, Samuel J. Reich was appointed CEO in January 2024. The company successfully completed an $85 million public offering of common stock and pre-funded warrants in March 2026, with proceeds primarily funding the continued development of SAB-142. SAB-142 has advanced into a registrational Phase 2b SAFEGUARD study, with enrollment expected to conclude by the end of 2026 and topline data anticipated in the second half of 2027. Positive confirmatory clinical results from the Phase 1 study of SAB-142, reported in December 2025, demonstrated a favorable safety profile without serum sickness or anti-drug antibodies. The company also strengthened its Board of Directors in January 2026 with the appointment of David Zaccardelli as Chair and Rita Jain as an independent director.